Opportunities for cell and gene therapy landscape remain high but so does challenges: GlobalData Read more
High ADHD comorbidity rates offer opportunity for pipeline products to capture market: GlobalData Read more
FDA denial could delay launch of Minerva’s schizophrenia treatment roluperidone by at least two years: GlobalData Read more
Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies: GlobalData Read more
Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData Read more
India pharma giants and global big pharma join forces for NMEs commercialisation in India: GlobalData Read more
Top 20 global biopharma companies report 1.6 per cent per cent market cap growth to $3.67 tn in 2023: GlobalData Read more